Abstract: Embodiments of the invention relate to a corrole according to formula [I]; wherein R1, R2, and R3 are each independently H, —COOH, CF3, or a halide selected from the group consisting of F—, Cl—, Br— and I, with the proviso that R1, R2, and R3 can not all be CF3, and when the compound is of Formula II, wherein M is a metallic ion or an elemental ion selected from the group consisting of an elemental ion of group 13-16 in row 3 or above and boron, preferably selected from the group consisting of: Fe, Mn, Ga, P, Mo, Re, Co and Cu, or a salt thereof. Methods for treatment, catalysis, and detection using the compounds are also described.

Abstract: Embodiments of the invention relate to compositions comprising a corrole and optionally a protein, wherein the composition are characterized by improved water solubility. The corrole may be a hydrophobic corrole, according to formula [I]. The protein may be a plasma protein. The plasma protein may be albumin. The compositions may be in nanoparticulate form.

Abstract: Embodiments of the invention relate to methods of treatment a cardiovascular disease in a patient comprising administering an effective amount of a statin or a pharmaceutically acceptable salt thereof in combination with an effective amount of a transition metal complex of a corrole, an optically active isomer thereof or a pharmaceutically acceptable salt thereof. Further embodiments refer to pharmaceutical compositions comprising a statin and a corrole. Optionally, the corrole has a structure: wherein; M is a transition metal selected from the group consisting of Mn, Fe, Ru, Co, V, Cr, and Cu and R1, R2, R3, X1, X2, X3X4; E2, E3, E17 and E18 are each defined as in the specification.

Abstract: An embodiment of the invention provides a use of an effective amount of a transition metal complex of a corrole, an optically active isomer thereof, or a pharmaceutically acceptable salt thereof for treating a disease of the eye and/or the kidney in a subject suffering from diabetes. An embodiment of the invention further provides a use of a transition metal complex of a corrole, an optically active isomer thereof, or a pharmaceutically acceptable salt thereof for lowering serum glucose and serum triglyceride levels in a subject suffering from diabetes.

Abstract: Metallocorrole complexes of third row transition metals (see Formula I below) may be used as therapeutic agents, catalysts, components of oxygen detectors, and components of light emitting diodes. In particular, metallocorrole complexes of third row transition metals may be used as improved photosenitizers in photodynamic therapy; as improved catalysts in aziridination, epoxidation, and water splitting reactions; as improved in vivo imaging agents; and as improved components in the emissive layer of OLEDs. Due to their strongly sigma-donating nature, corroles are able to stabilize third row transition metals in high oxidation states. Third row transition metals are significantly more electropositive than their first and second row counterparts and may therefore act as improved catalysts.

Abstract: An embodiment of the invention provides a use of an effective amount of a transition metal complex of a corrole, an optically active isomer thereof, or a pharmaceutically acceptable salt thereof for treating a disease of the eye and/or the kidney in a subject suffering from diabetes. An embodiment of the invention further provides a use of a transition metal complex of a corrole, an optically active isomer thereof, or a pharmaceutically acceptable salt thereof for lowering serum glucose and serum triglyceride levels in a subject suffering from diabetes.

Abstract: Transition metal complexes of amphiphilic/bipolar corroles, optically active isomers or pharmaceutically acceptable salts thereof are useful for prevention of a cardiovascular disease or disorder in a subject susceptible to develop such a cardiovascular disease or disorder.

Abstract: Embodiments of the invention relate to methods of treatment a cardiovascular disease in a patient comprising administering an effective amount of a statin or a pharmaceutically acceptable salt thereof in combination with an effective amount of a transition metal complex of a corrole, an optically active isomer thereof or a pharmaceutically acceptable salt thereof. Further embodiments refer to pharmaceutical compositions comprising a statin and a corrole.

Abstract: Metallocorrole complexes of third row transition metals (see Formula I below) may be used as therapeutic agents, catalysts, components of oxygen detectors, and components of light emitting diodes. In particular, metallocorrole complexes of third row transition metals may be used as improved photosenitizers in photodynamic therapy; as improved catalysts in aziridination, epoxidation, and water splitting reactions; as improved in vivo imaging agents; and as improved components in the emissive layer of OLEDs. Due to their strongly sigma-donating nature, corroles are able to stabilize third row transition metals in high oxidation states. Third row transition metals are significantly more electropositive than their first and second row counterparts and may therefore act as improved catalysts.

Abstract: Metallocorrole complexes of third row transition metals (see Formula I below) may be used as therapeutic agents, catalysts, components of oxygen detectors, and components of light emitting diodes. In particular, metallocorrole complexes of third row transition metals may be used as improved photosenitizers in photodynamic therapy; as improved catalysts in aziridination, epoxidation, and water splitting reactions; as improved in vivo imaging agents; and as improved components in the emissive layer of OLEDs. Due to their strongly sigma-donating nature, corroles are able to stabilize third row transition metals in high oxidation states. Third row transition metals are significantly more electropositive than their first and second row counterparts and may therefore act as improved catalysts.

Abstract: Transition metal complexes of amphiphilic corroles, optical isomers and pharmaceutically acceptable salts thereof are useful for neuroprotection and neurorescue, particularly for treatment of diabetes and neurodegenerative diseases. The amphiphilic corrole is preferably a 5,10,15-tris-aryl- or 5,10,15-tris-CF3-corrole, and said transition metal complex more preferably has the formula I defined in the specification. Also provided are propargyl-containing corroles carrying one or more radicals substituted by a propargylamino group or one or more nitrogen-containing heteroaryl radicals substituted by propargyl at the ring N atom.

Abstract: Transition metal complexes of amphiphilic/bipolar corroles, optically active isomers or pharmaceutically acceptable salts thereof are useful for prevention of a cardiovascular disease or disorder in a subject susceptible to develop such a cardiovascular disease or disorder.

Abstract: Transition metal complexes of amphiphilic corroles, optical isomers and pharmaceutically acceptable salts thereof are useful for neuroprotection and neurorescue, particularly for treatment of diabetes and neurodegenerative diseases. The amphiphilic corrole is preferably a 5,10,15-tris-aryl- or 5,10,15-tris-CF3-corrole, and said transition metal complex more preferably has the formula I defined in the specification. Also provided are propargyl-containing corroles carrying one or more radicals substituted by a propargylamino group or one or more nitrogen-containing heteroaryl radicals substituted by propargyl at the ring N atom.

Abstract: Metallocorrole complexes of third row transition metals may be used as therapeutic agents, catalysts, components of oxygen detectors, and components of light emitting diodes. In particular, metallocorrole complexes of third row transition metals may be used as improved photosenitizers in photodynamic therapy; as improved catalysts in aziridination, epoxidation, and water splitting reactions; as improved in vivo imaging agents; and as improved components in the emissive layer of OLEDs. Due to their strongly sigma-donating nature, corroles are able to stabilize third row transition metals in high oxidation states. Third row transition metals are significantly more electropositive than their first and second row counterparts and may therefore act as improved catalysts.

Abstract: Corroles of formula I, wherein Ar is aryl or heteroaryl; M is absent or is a metal selected from Al, Ga, Co, Mn, Fe, Ru, Sn, Cr or Rh; E2, E3 and E17, the same or different, each is H, SO2Cl, SO3H, SO2NR1R2, CO2H, CO2R, COC1, CONR1R2, CHO or NO2, R is alkyl or aryl, and R1 and R2, the same or different, each is H, alkyl, aryl or together with the N atom to which they are attached form a saturated 5-6 membered ring optionally containing a further heteroatom selected from O, S and N; and E18 is H or CHO; or E3 and E18 are H and E2 and E17 are each SO2, both SO2 groups being linked by a bridge R3N(R4)-phenyl-(R4)NR3, wherein R3 is H, alkyl, phenyl or aralkyl, and R4 is alkylene; and provided that at least one of E2, E3, E17 and E18 is not H, are provided. The corroles can be used for tumor detection and treatment, in photovoltaic devices, as catalysts and as intermediates.

Abstract: Corroles of formula I, wherein Ar is aryl or heteroaryl; M is absent or is a metal selected from Al, Ga, Co, Mn, Fe, Ru, Sn, Cr or Rh; E2, E3 and E17, the same or different, each is H, SO2Cl, SO3H, SO2NR1R2, CO2H, CO2R, COC1, CONR1R2, CHO or NO2, R is alkyl or aryl, and R1 and R2, the same or different, each is H, alkyl, aryl or together with the N atom to which they are attached form a saturated 5-6 membered ring optionally containing a further heteroatom selected from O, S and N; and E18 is H or CHO; or E3 and E18 are H and E2 and E17 are each SO2, both SO2 groups being linked by a bridge R3N(R4)-phenyl-(R4)NR3, wherein R3 is H, alkyl, phenyl or aralkyl, and R4 is alkylene; and provided that at least one of E2, E3, E17 and E18 is not H, are provided. The corroles can be used for tumor detection and treatment, in photovoltaic devices, as catalysts and as intermediates.

Abstract: Tertrapyrrolic macrocycles selected from 5,10,15,20-tetraaryl-porphyrins and 5,10,15-triaryl-corrloes, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, inhibit growth factor (e.g. bFGF, VEGF) receptor tyrosine kinase activity, and are useful for inhibition of cell proliferation mediated by growth factor receptor tyrosine kinase activity for example for inhibition of angiogenesis, or vascular smooth muscle cell proliferation in disorders including atherosclerosis, hyperthrophic heart failure and postsurfical restenosis, and of cell proliferation and migration in the treatment of primary tumors and metastasis. Some of the 5,10,15,20-tetraaryl-prophyrins are novel compounds.

Abstract: A new process for the preparation of corroles, having the structure of formula I below relies on a solvent-free condensation of an aldehyde with a pyrrole. Further disclosed are several new corroles, salts, optically active isomers and complexes thereof synthesized using the process.